NCT00305708View on ClinicalTrials.gov

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions
Congenital Amegakaryocytic ThrombocytopeniaDiamond-blackfan AnemiaFanconi AnemiaLeukemiaSevere Congenital NeutropeniaThrombocytopenia
Interventions
BIOLOGICAL

anti-thymocyte globulin

DRUG

busulfan

DRUG

fludarabine phosphate

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

PROCEDURE

umbilical cord blood transplantation

RADIATION

radiation therapy

Trial Locations (1)

94115

UCSF Comprehensive Cancer Center, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Francisco

OTHER

NCT00305708 - Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission | Biotech Hunter | Biotech Hunter